BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES
First Claim
Patent Images
1. A bispecific antibody binding to EGFR and IGF-1R comprising a first antigen-binding site that binds to EGFR and a second antigen-binding site that binds to IGF-1R, characterized in thati) said antigen-binding sites are each a pair of an antibody heavy chain variable domain and an antibody light chain variable domain;
- ii) said first antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
1, a CDR2 region of SEQ ID NO;
2, and a CDR1 region of SEQ ID NO;
3, and in the light chain variable domain a CDR3 region of SEQ ID NO;
4, a CDR2 region of SEQ ID NO;
5, and a CDR1 region of SEQ ID NO;
6; and
iii) said second antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
11, a CDR2 region of SEQ ID NO;
12, and a CDR1 region of SEQ ID NO;
13, and in the light chain variable domain a CDR3 region of SEQ ID NO;
14, a CDR2 region of SEQ ID NO;
15, and a CDR1 region of SEQ ID NO;
16;
or said second antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
17, a CDR2 region of SEQ ID NO;
18, and a CDR1 region of SEQ ID NO;
19, and in the light chain variable domain a CDR3 region of SEQ ID NO;
20, a CDR2 region of SEQ ID NO;
21, and a CDR1 region of SEQ ID NO;
22.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies.
-
Citations
8 Claims
-
1. A bispecific antibody binding to EGFR and IGF-1R comprising a first antigen-binding site that binds to EGFR and a second antigen-binding site that binds to IGF-1R, characterized in that
i) said antigen-binding sites are each a pair of an antibody heavy chain variable domain and an antibody light chain variable domain; -
ii) said first antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
1, a CDR2 region of SEQ ID NO;
2, and a CDR1 region of SEQ ID NO;
3, and in the light chain variable domain a CDR3 region of SEQ ID NO;
4, a CDR2 region of SEQ ID NO;
5, and a CDR1 region of SEQ ID NO;
6; andiii) said second antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
11, a CDR2 region of SEQ ID NO;
12, and a CDR1 region of SEQ ID NO;
13, and in the light chain variable domain a CDR3 region of SEQ ID NO;
14, a CDR2 region of SEQ ID NO;
15, and a CDR1 region of SEQ ID NO;
16;or said second antigen-binding site comprises in the heavy chain variable domain a CDR3 region of SEQ ID NO;
17, a CDR2 region of SEQ ID NO;
18, and a CDR1 region of SEQ ID NO;
19, and in the light chain variable domain a CDR3 region of SEQ ID NO;
20, a CDR2 region of SEQ ID NO;
21, and a CDR1 region of SEQ ID NO;
22. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
Specification